C12N 2795/10071
Demonstrated in vivo effect
C12N2795/10071 (Demonstrated in vivo effect) appears on 4 US grants and 8 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 8
- Assignees
- 7
- Inventors
- 30
- Latest grant
- 13 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 0 |
| 2018 | 1 | 1 |
| 2019 | 1 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 0 |
| 2025 | 1 | 2 |
By publication year.
Recent patents
- Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)13 May 2025US 12,296,002 B2Dynavax Technologies Corporation
- Dimeric bacteriophage lysins27 Aug 2019US 10,392,608 B2The Rockefeller University
- Dimeric bacteriophage lysins13 Mar 2018US 9,914,916 B2The Rockefeller University
- Dimeric bacteriophage lysins8 Mar 2016US 9,279,118 B2The Rockefeller University
- Polyvalent bacteriophage compositions and methods for treatment of bacterial infections20 Nov 2025US 2025/0352592 A1Baylor College of Medicine
- Targeting e coli cells26 Jun 2025US 2025/0205293 A1SNIPR Biome ApS
- Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof14 Dec 2023US 2023/0398161 A1Locus Biosciences, Inc.
- Coronavirus vaccines comprising a tlr9 agonist13 Apr 2023US 2023/0110516 A1Dynavax Technologies Corporation
- Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (sars-cov-2)7 Oct 2021US 2021/0308257 A1Dynavax Technologies Corporation
Most cited
By later US patents